Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 12

Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study

Sayfa
1019–1028
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey.
📊
Temel Bulgular & Veri:Methods: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study.
💡
Sonuç & Katkı:HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aims: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey. Methods: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study. Data on patient characteristics, etiologies of HCC, laboratory values, and tumor characteristics and stages were recorded at study enrollment. Results: HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and NAFLD (3.5%), as the major etiologies. Considering that 51.6% of the patients had >5 cm HCC, 44% were Child–Pugh B/C and 57% were BCLC B-D, it appears that a significant group of HCC patients were diagnosed at advanced stages. Of 540 patients, 271 (50.2%) were referred or applied with the diagnosis of HCC. Patients with HCC at presentation had larger tumor size (median (min-max) 6.6 (0-30) vs. 4.8 (0-90) cm, P < .001) and more advanced BCLC stage (Stage C-D in 40.8% vs. 26.4%, respectively, P = .005), compared to patients who were diagnosed during follow-up. Conclusions: Our findings revealed that HBV infection was the leading etiology and a moderate-to-advanced disease was evident in more than half of patients at the time of diagnosis. HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.

🔖

Bu Makaleye Atıf Yap

AKARCA, U. S., ÜNSAL, B., SEZGİN, O., YALÇIN, K., KAYHAN, M. A., GONEN, C., GÜNDÜZ, F., OZENİRLER, S., SONSUZ, A., DİNÇER, D., TEKİN, S. B., YUCEL, I., AKBULUT, H., ALKIM, C., ÖZYILKAN, Ö., CEVİK, Z. M., IDİLMAN, R. (2021). Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 12, 1019–1028. https://ajindex.com/articles/399382

Kaynakça (5)

  1. World Health Organization, International Agency for Research on Cancer. Global Cancer Observatory (GCO). Available at: http: //glo bocan.iarc.fr/o ld/Fa ctShe ets/c ancer s/liv er-ne w.asp. Accessed January 01, 2021
  2. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population- based study. Lancet Oncol. 2014;15(1):23-34. [CrossRef] 3. Goutté N, Sogni P, Bendersky N, et al. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66(3):537-544. [CrossRef]
  3. Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302- 309. [CrossRef]
  4. Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):607- 617. [CrossRef] 6. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526-549. [CrossRef] 7. Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: present and future. Med Clin (Barc). 2018;150(10):390-397. [CrossRef] 8. Turkish Ministry of Health General Directorate of Public Health. Turkey Cancer Statistics 2016. Ankara, 2019. Avaliable at: https://hs gm.sa glik. gov.t r/tr/ kanse r-ist atist ikler i. Accessed March 15, 2020
  5. Krishan S, Dhiman RK, Kalra N, et al. Joint consensus statement of the Indian National Association for study of the liver and Indian Radiological and Imaging Association for the diagnosis and imaging of hepatocellular carcinoma incorporating liver imaging reporting and data system. J Clin Exp Hepatol. 2019;9(5):625-651. [CrossRef] 10. Alacacioglu A, Somali I, Simsek I, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol. 2008;38(10):683-688. [CrossRef] 11. Ekinci O, Baran B, Ormeci AC, et al. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol. 2018;10(1):51-61. [CrossRef] 12. Iliaz R, Yuce T, Torun S, et al. Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis. Eur J Gastroenterol Hepatol. 2019;31(10):1247- 1249. [CrossRef] 13. Trad D, Bibani N, Sabbah M, et al. Known, new and emerging ris